Emerging Epigenetic Therapies for Brain Tumors

Area of Science:

• Neuro-oncology
• Cancer epigenetics
• Molecular oncology

Background:

• Malignant brain tumors like glioblastoma and medulloblastoma have poor prognoses due to limited treatment options.
• Aberrant epigenetics, including DNA methylation and histone modifications, are hallmarks of these aggressive brain cancers.
• There is a critical need for novel therapeutic strategies to overcome treatment resistance in brain malignancies.

Purpose of the Study:

• To review emerging epigenetic-targeted therapies for malignant brain tumors.
• To highlight treatments currently in the discovery phase and clinical trials.
• To discuss the potential of epigenetic drugs to reverse tumor-specific epigenetic deregulation.

Main Methods:

• Literature review of recent preclinical and clinical studies on epigenetic therapies for brain tumors.
• Analysis of drugs targeting epigenetic regulators such as DNA methyltransferases and histone deacetylases.
• Focus on therapies showing promise in addressing glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma.

Main Results:

• Epigenetic deregulation is a key feature driving the development and progression of malignant brain tumors.
• Various epigenetic drugs targeting DNA methylation, histone modifications, and noncoding RNAs show therapeutic potential.
• Several epigenetic-targeted therapies are advancing through discovery and clinical trials for brain cancer.

Conclusions:

• Epigenetic-targeted therapies represent a promising alternative treatment modality for intractable malignant brain tumors.
• Reversing epigenetic dysregulation offers a viable strategy to improve outcomes for patients with brain malignancies.
• Continued research and clinical evaluation of these novel therapies are crucial for advancing brain tumor treatment.